Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for HPV-16/18 Related Cervical HSIL
NCT03185013Phase 3Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in cervical squamous intraepithelial lesion (SIL) comparing VGX-3100 + EP with Placebo + EP (2 arms). Primary endpoint: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples at 36 weeks. Started Jun 2017; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical squamous intraepithelial lesion (SIL)
Beyond the preview
Go deeper on NCT03185013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185013.